Brain imaging responses to food in insulin resistance - screening

Brain imaging responses to food in insulin resistance: a single centre non-randomised interventional screening trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18732138

Enrollment

100

Registered

2010-12-14

Start date

2010-12-01

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Diabetes Research Network

Interventions

Volunteers will attend a screening visit to determine their eligibility to enter the intervention study (UKCRN 9117

DRN 518

ISRCTN51099878) according to the inclusion criteria. This will include completing validated questionnaires of eating behaviour to exclude the presence of eating disorders. Volunteers will also provide

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: All subjects (insulin sensitive and insulin resistant): 1. Men 2. Age 18 - 65 years (inclusive at time of recruitment) 3. Right-handed 4. English speaking 5. No active medical illness including diabetes mellitus 6. Body mass index (BMI) less than or equal to 30 kg/m2 Insulin sensitive subjects: 7. No family history of diabetes mellitus 8. Insulin sensitive (determined by homeostatic model assessment - insulin resistance [HOMA2-IR] during screening process) Insulin resistant subjects: 9. First degree relatives of patients with type 2 diabetes mellitus 10. Insulin resistance (determined by HOMA2-IR during screening process)

Exclusion criteria

Exclusion criteria: 1. Women 2. Left-handedness 3. Current of past history of significant substance abuse or eating disorder 4. Neurological or psychiatric disorders 5. Use of medication that may affect brain activity (e.g. antidepressants, anticonvulsants, antipsychotic drugs), drugs for obesity (orlistat or sibutramine) or drugs that lower glucose (e.g. metformin, sulphonylureas, thiazolidinediones, incretins or insulin) 6. Inability to understand spoken and/or written English 7. Claustrophobia (because of the small bore of the MR scanner) 8. BMI greater than 30 kg/m2 9. Contraindication to MRI (pacemaker in situ, extensive dental work, history of penetrating eye trauma, presence of metal surgical clips etc.) 10. Presence of diabetes

Design outcomes

Primary

Measure	Time frame
Insulin sensitivity and glycaemic status, results of intervention to be available within a maximum of one month of completing screening process	—

Secondary

Measure	Time frame
Eating behaviour, determined during screening visit	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026